What Sandostatine Treats: Main Uses and Benefits

This medication is used in situations involving certain distressing symptoms related to systemic imbalance in patients with Acromegaly. The medicine is commonly used when initial treatments like surgery or radiation have not provided sufficient control. This therapeutic support is commonly used to help with groups of symptoms that may become intense or disruptive, such as chronic headaches, excessive sweating, and joint pain.

Sandostatine is also applied in addressing acute or disruptive symptom patterns associated with functioning Neuroendocrine Tumors (NETs), including Carcinoid Syndrome and VIPomas. This includes the use for managing debilitating manifestations like symptoms related to systemic imbalance such as severe diarrhea and symptoms associated with acute or episodic changes like severe flushing. It is also considered relevant when short-term symptomatic assistance is needed in situations involving bleeding associated with esophageal varices.

“This therapeutic support contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms become more noticeable.”

---

Quick Fact: Symptomatic Support

Sandostatine assists with maintaining functional stability by addressing symptoms related to systemic imbalance, often used when symptoms intensify and supportive relief is needed. It contributes to easing the overall symptom load across conditions characterized by periods of heightened symptoms.

Who Can and Cannot Use Sandostatine?

The eligibility for Sandostatine (octreotide) is determined by specific population and condition criteria established in official regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Official Eligibility Constraints

Population Group	Regulatory Status	Constraint Detail
Adults	Established Use	Use is established for the approved indications.
Pediatric Patients	Use Not Established	Safety and efficacy have not been formally established in the pediatric population.
Hypersensitivity	Contraindicated	Use is strictly prohibited for patients with a known hypersensitivity to octreotide or any component of the formulation.
Pregnancy	Special Consideration	Use is generally preferably avoided due to limited clinical data; should only be considered if the necessity is clear.
Hepatic/Renal Impairment	Conditional Use	Dose adjustments may be necessary for patients with significant liver impairment (e.g., cirrhosis) or severe renal impairment, as these conditions can alter drug clearance.

Females of reproductive potential should be advised of the potential for restoration of fertility and the need to use adequate contraception during therapy.

Sandostatine Interactions with other medicines and products

Officially documented interaction patterns for Sandostatine (Octreotide) are classified by regulatory authorities based on the drug's potential to modify the systemic exposure of co-administered medicines and its influence on physiological function.

---

Alterations to Drug Exposure

Octreotide may modify the concentration of certain co-administered drugs. Co-administration may result in reduced relative bioavailability and systemic exposure of Cyclosporine. Conversely, concomitant use may lead to increased serum concentrations of Bromocriptine. Furthermore, regulatory caution is required for drugs primarily metabolized by the CYP3A4 enzyme system, particularly those with a narrow therapeutic index, as Octreotide may alter their metabolic clearance.

Pharmacodynamic and Procedural Restrictions

Pharmacodynamic interactions involve additive effects. Octreotide's inhibitory effects on insulin and glucagon secretion necessitate close monitoring of blood glucose when used concurrently with Insulin and Oral Hypoglycemic Agents. Additive effects on cardiac function are noted with co-administration of Beta-Blockers and Calcium Channel Blockers, due to the drug's association with bradycardia. A mandatory procedural restriction requires that Sandostatine LAR Depot be discontinued for at least four weeks prior to the administration of Lutetium Lu 177 Dotatate Injection. Regulatory information also documents that drug clearance is decreased in patients with hepatic impairment (cirrhosis) and in the elderly population.

Molecular Agonism and the Core Inhibitory Switch

The mechanism of octreotide is defined by its role as a highly selective agonist of the somatostatin receptors ( SSTRs), particularly the SSTR2 subtype, which are expressed on endocrine cells. By binding to and activating these receptors, the drug engages the inhibitory G i protein cascade, which initiates a signal by inhibiting adenylyl cyclase and blocking the necessary calcium ion ( Ca^2+) influx.

---

Inhibition of Secretion and Systemic Modulation

The molecular cascade directly translates into the inhibition of secretory vesicle fusion with the cell membrane, leading to a profound, systemic suppression of regulatory peptide release. This mechanism modulates cellular signaling across the body, resulting in key physiological consequences such as the reduced transport of fluid and electrolytes into the small intestine and localized vasoconstriction in the digestive tract circulation. This modulation of glandular secretion and local hemodynamics characterizes the drug's mechanism of action.

Sandostatine (octreotide acetate) is a synthetic analog of the naturally occurring hormone somatostatin. It is administered by injection, with the specific route, dosage, and formulation depending on the condition being treated.

Administration Routes and Formulations

Sandostatine is available in two primary forms, each requiring a distinct administration technique:

1. Sandostatine Injection (Immediate-Release Solution): This formulation can be given via subcutaneous (SC) injection or intravenously (IV). Subcutaneous injection is the most common route, often self-administered, typically three times daily (t.i.d.). Intravenous administration is generally reserved for hospital settings or emergency situations, such as a carcinoid crisis, and may be given as a slow IV push over 3 minutes or as an infusion over 15 to 30 minutes. Sites for subcutaneous injection should be rotated systematically to help minimize injection-site pain. The injection should be allowed to reach room temperature before use to reduce local discomfort.

2. Sandostatine LAR Depot (Long-Acting Release Powder for Suspension): This formulation must be administered once every four weeks by a healthcare professional as a deep intramuscular (IM) injection, typically into the gluteal muscle. It must be carefully reconstituted with the supplied diluent and injected immediately after mixing. This form is not for intravenous use.

General Dosage and Monitoring

Dosage is highly individualized based on the patient's condition, response, and tolerability. For both carcinoid tumors and acromegaly, treatment often begins with the immediate-release formulation to establish tolerance and an effective dose before switching to the long-acting depot injection.

• Titration and Monitoring: The dose is adjusted based on biochemical markers (such as Growth Hormone and IGF-I levels for acromegaly, or symptoms for carcinoid tumors) and the patient's symptoms.
• Important Note: Do not mix Sandostatine with Total Parenteral Nutrition (TPN) solutions, as this can reduce the drug's efficacy. Patients on chronic therapy should be periodically monitored for cardiac function, glucose levels (risk of hypo- or hyperglycemia), thyroid function, and the formation of gallstones (cholelithiasis).

Sandostatine: Recent Clinical Evidence

Clinical research involving Sandostatine (octreotide) continues to focus primarily on its established uses in Acromegaly and Neuroendocrine Tumors (NETs), particularly those causing carcinoid syndrome.

Clinical Trial Findings

In Acromegaly, studies have investigated the drug's effect on suppressing the excessive production of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Phase 3 trials have compared octreotide to placebo or other long-acting somatostatin analogues. For patients previously controlled on injectable therapy, research has also explored the safety and efficacy of oral octreotide capsules as an alternative option for maintaining biochemical control.

For functioning NETs, research centers on symptom management, especially diarrhea and flushing associated with carcinoid syndrome. Studies have examined the effect of the long-acting release (LAR) formulation in controlling these symptoms. Some systematic reviews have focused on patients whose symptoms are refractory to conventional dosing, examining the reported use of doses higher than the initially approved range to evaluate potential symptomatic benefit.

Safety and New Formulations

Newer formulations of octreotide, such as subcutaneous depot injections, have been assessed in Phase 2 trials. These studies primarily compared the pharmacokinetic profile and tolerability of the subcutaneous depot to the established intramuscular (IM) LAR injection in patients with acromegaly or functioning NETs. Reported adverse events remain consistent with the known profile of octreotide, primarily involving gastrointestinal disorders and injection site reactions.

Ongoing clinical investigation includes studies clarifying whether octreotide therapy may be associated with reduced postoperative weight loss or improved nutritional recovery following surgery for certain cancers, though evidence in these areas remains exploratory.

Common questions about Sandostatine (FAQ)

---

Q: How quickly does Sandostatine start working to help with flushing or diarrhea?

A: Regulatory information indicates that the immediate-release solution (Sandostatine Injection) has a plasma half-life of less than two hours. While the drug starts acting quickly, its effects can persist for up to 12 hours depending on the condition being treated. For long-acting forms, the medicine is released slowly over several weeks to provide sustained control of symptoms.

---

Q: Does Sandostatine affect my blood sugar levels?

A: Yes, official product information states that Sandostatine can cause changes in blood glucose levels, including both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). Because of this risk, individuals may be monitored, and any concurrent anti-diabetic treatments may require medical adjustment.

---

Q: Can Sandostatine affect my thyroid function?

A: Official labeling notes that Sandostatine may affect the thyroid gland, and hypothyroidism (low thyroid hormone levels) may occur. Because of this potential effect, regulatory guidelines indicate that monitoring of thyroid levels may be performed periodically for individuals receiving chronic treatment.

---

Q: Does Sandostatine interact with common vitamins or herbal supplements?

A: Official safety data indicates that Sandostatine may interfere with the absorption of nutrients. Long-term use is associated with a decrease in Vitamin B12 levels. Due to this, individuals on chronic therapy may require monitoring of B12 levels, and replacement may be necessary in some cases.

---

Q: What kind of monitoring tests are usually done while taking Sandostatine?

A: Official information advises that individuals on chronic treatment are periodically monitored for several factors. These include cardiac function (due to the risk of slow heart rate), glucose levels (due to blood sugar risks), thyroid function, and the potential formation of gallstones (cholelithiasis).

---

Q: Why do doctors check vitamin B12 levels when a patient is on Sandostatine?

A: Doctors monitor Vitamin B12 levels because long-term treatment with Sandostatine is associated with a decrease in this essential vitamin. This is due to the drug's effect on nutrient and fat absorption, which can lead to steatorrhea (fat in stool).

---

Q: Does Sandostatine affect liver or kidney function tests?

A: Regulatory documents indicate that the drug's clearance is slower in patients with existing severe renal impairment (kidney disease) or cirrhosis of the liver (hepatic impairment). Although dose adjustments may be needed, specific information on how the drug affects standard liver or kidney function tests is not detailed.

---

Q: Does Sandostatine cause weight gain or weight loss?

A: Weight changes are listed in the official side effect profile. Regulatory data lists a decrease in weight as an uncommon reaction, meaning it affects a small percentage (1% to 4%) of patients.

---

Q: What are the most common side effects people complain about with Sandostatine injections?

A: The most common side effects (Very Common, affecting 10% or more of patients) are mainly related to the gastrointestinal system and the injection site. These frequently reported issues include diarrhea, abdominal pain, nausea, and local injection site reactions.

---

Q: Is it normal to feel tired or weak after a Sandostatine injection?

A: Regulatory data lists generalized weakness (asthenia) and fatigue as uncommon adverse reactions, meaning they are reported in 1% to 4% of patients. Rigors (shaking) are listed as a less common reaction.

---

Q: Is Sandostatine used for different types of neuroendocrine tumors (NETs)?

A: Yes, official regulatory documents indicate that Sandostatine is approved for managing symptoms associated with various types of functional gastro-entero-pancreatic tumors. These include tumors such as Carcinoid tumors, VIPomas, Glucagonomas, Gastrinomas, and Insulinomas.

---

Q: What kind of research is being done on new uses for Sandostatine?

A: The main focus of clinical research remains on its established uses in Acromegaly and NETs, and on developing new delivery methods, such as oral capsules. For certain advanced midgut NETs, studies have focused on the ability of the long-acting formulation to control tumor growth.

---

Q: Can Sandostatine affect my appetite?

A: Regulatory data lists a decrease in appetite, medically referred to as anorexia, as an uncommon adverse reaction. This means it has been reported in a small percentage (1% to 4%) of patients.

---

Q: How long can someone stay on Sandostatine treatment?

A: Treatment with Sandostatine for conditions like Acromegaly or NETs is often chronic (long-term). However, official warnings note that the development of gallstone formation is strongly associated with long-term use.

---

Q: Are there any long-term side effects of Sandostatine that I should worry about?

A: For individuals on chronic therapy, key long-term risks documented in official safety information include the potential for gallstone formation (cholelithiasis). Additionally, long-term use requires monitoring for potential decreases in Vitamin B12 levels and changes in thyroid function.

---

Q: Will Sandostatine stop tumor growth or just control symptoms?

A: The use of Sandostatine is approved for both purposes, depending on the condition. For carcinoid tumors, the injection is indicated for symptomatic treatment (diarrhea/flushing). However, the long-acting depot form is also indicated to control tumor growth in patients with certain advanced midgut Neuroendocrine Tumors (NETs).

---

Q: Can children or teenagers be treated with Sandostatine?

A: Official regulatory documents state that the safety and effectiveness of Sandostatine have not been formally established in the general pediatric population. Safety warnings also note that serious adverse events have been reported in children.

---

Q: What should I do if the injection site for Sandostatine is red or sore?

A: Injection site reactions, including pain, redness, or swelling, are common. Regulatory guidelines indicate that rotating subcutaneous injection sites systematically may help minimize pain and local irritation.

---

Q: Why is Sandostatine sometimes used before surgery for certain conditions?

A: The drug is officially indicated for the pre-operative control of hypoglycemia (low blood sugar) in patients with specific rare tumors called Insulinomas. This use is intended to stabilize hormone levels before a surgical procedure.

---

Q: Is it normal for my stomach to hurt after starting Sandostatine?

A: Yes, abdominal pain is listed in regulatory documents as a Very Common side effect. This means it is reported to affect 1 in 10 or more patients.

---

Q: Is the short-acting Sandostatine injection painful?

A: Injection site reactions, including pain, are listed as Very Common side effects. To help reduce local discomfort, regulatory guidance advises allowing the Sandostatine injection to reach room temperature before administration.

---

Q: Can Sandostatine cause mood changes or depression?

A: Official adverse reaction data lists both depression and anxiety as less common adverse reactions. This means they occur in a small percentage (1% to 4%) of patients.

---

Q: What is the 'rebound effect' people mention when stopping Sandostatine?

A: In some patients with Acromegaly who have received pituitary irradiation, regulatory guidance suggests the drug should be withdrawn yearly to assess disease activity. If symptoms or hormone levels sharply recur or increase upon withdrawal, therapy may need to be resumed.

---

Q: Does Sandostatine have a generic version available?

A: Yes, the active ingredient, octreotide acetate, is available in generic form. This includes both the immediate-release injection and the long-acting depot formulation.

Storage and Disposal Requirements for Sandostatin®

This medication requires specific storage conditions to maintain its quality, as documented in regulatory labeling.

Storage Conditions

For long-term storage, Sandostatin (octreotide acetate) must be kept refrigerated at a temperature range of 2 C to 8 C (36 F to 46 F). The product must be stored in its original container and protected from light. It is a mandatory instruction to not freeze the product.

Unopened vials may be stored at controlled room temperature (20 C to 30 C) for a maximum of 14 days. Once a multi-dose vial has been accessed, the contents are stable for 14 days at room temperature. The prefilled pen is stable for 28 days at room temperature after its first use, with the pen cap on.

Disposal

Sandostatin must be stored out of the sight and reach of children. Unused or expired medication must be disposed of in accordance with local regulatory requirements. Used needles and syringes must be placed immediately into a dedicated puncture-proof sharps container.